1.675
price down icon4.29%   -0.075
 
loading
前日終値:
$1.75
開ける:
$1.83
24時間の取引高:
93,810
Relative Volume:
0.40
時価総額:
$22.74M
収益:
$1.89M
当期純損益:
$-17.92M
株価収益率:
-0.2504
EPS:
-6.69
ネットキャッシュフロー:
$-15.62M
1週間 パフォーマンス:
+10.20%
1か月 パフォーマンス:
+6.01%
6か月 パフォーマンス:
-23.17%
1年 パフォーマンス:
-4.29%
1日の値動き範囲:
Value
$1.67
$1.83
1週間の範囲:
Value
$1.45
$1.83
52週間の値動き範囲:
Value
$0.7707
$6.40

Longeveron Inc Stock (LGVN) Company Profile

Name
名前
Longeveron Inc
Name
セクター
Healthcare (1155)
Name
電話
305-302-7158
Name
住所
1951 NW 7TH AVENUE, MIAMI
Name
職員
25
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
LGVN's Discussions on Twitter

LGVN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
LGVN
Longeveron Inc
1.68 22.74M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.11 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.30 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.82 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.02 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.50 24.70B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-06 開始されました ROTH MKM Buy

Longeveron Inc (LGVN) 最新ニュース

pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 22, 2025

Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan

Apr 22, 2025
pulisher
Apr 10, 2025

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha

Apr 10, 2025
pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 20, 2025

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register

Mar 03, 2025
pulisher
Mar 03, 2025

LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews

Mar 03, 2025
pulisher
Mar 02, 2025

Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada

Mar 02, 2025
pulisher
Mar 02, 2025

Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 02, 2025
pulisher
Feb 28, 2025

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan

Feb 28, 2025
pulisher
Feb 26, 2025

LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Feb 26, 2025
pulisher
Feb 23, 2025

Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

Longeveron® Announces World Health Organization Approval of “laro - The National Law Review

Feb 21, 2025
pulisher
Feb 21, 2025

LGVNRLongeveron Latest Stock News & Market Updates - StockTitan

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq

Feb 21, 2025
pulisher
Feb 18, 2025

Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron® Announces World Health Organization Approval of - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan

Feb 18, 2025
pulisher
Feb 14, 2025

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan

Feb 14, 2025
pulisher
Feb 05, 2025

Longeveron announces board member resignation - MSN

Feb 05, 2025

Longeveron Inc (LGVN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
大文字化:     |  ボリューム (24 時間):